Each week the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical company Daiichi Sankyo made a $10m pledge yesterday to Hatch Biofund 1, a US-based venture capital fund formed by non-profit medical research organisation Baruch S. Blumberg Institute. Hatch Biofund has a $50m target for its close, and Daiichi Sankyo’s commitment was made in connection with a collaboration agreement with life sciences incubator Pennsylvania Biotechnology…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.